Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study-Reference-Cited by-同舟云学术

Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study

Published:2018-06-18 Issue:12 Volume:59 Page:2821-2828
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Wang Zhao¹,Fang Xiaojie¹,Huang He¹,Hong Huangming¹,Li Xueying¹,Guo Chengcheng¹,Fu Xiaohong²,Zhang Mengping³,Lam Sio Teng⁴,Li Shanshan⁵,Li Fangfang¹,Peng Chen¹,Tian Ying¹,Lin Tongyu¹

Affiliation:

1. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China;

2. Shenzhen Sixth People's Hospital, Shenzhen, China;

3. Sun Yat-sen University First Affiliated Hospital, Guangzhou, China;

4. Centro Hospitalar Conde de Sao Januario, Macau, China;

5. Sun Yat-sen University Sixth Affiliated Hospital, Guangzhou, China

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1459605

Reference34 articles.

1. High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review